TABLE 2.
Demographic and clinical characteristics of total and resected gastric cancer patients without distant metastasis 1
| The US, 2004–15 | Netherlands, 2005‐14 | Belgium, 2004‐13 | Sweden, 2006‐16 | Norway, 2003‐14 | Slovenia, 2003‐13 | Estonia, 2009‐14 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Category | Total | Resected | Total | Resected | Total | Resected | Total | Resected | Total | Resected | Total | Resected | Total | Resected |
| n | 37 829 | 25 070 (66) | 9745 | 6605 (68) | 6468 | 5096 (79) | 4486 | 2501 (56) | 3258 | 2057 (63) | 2893 | 2172 (75) | 1028 | 807 (79) | |
| Sex | Male | 24 063 (64) | 15 989 (64) | 6287 (65) | 4367 (66) | 4274 (66) | 3420 (67) | 2821 (63) | 1587 (63) | 2036 (62) | 1323 (64) | 1821 (63) | 1384 (64) | 568 (55) | 445 (55) |
| Age at diagnosis | Year; as continuous | 69 ± 13 | 67 ± 13 | 71 ± 12 | 68 ± 12 | 70 ± 13 | 69 ± 12 | 72 ± 12 | 69 ± 11 | 72 ± 12 | 70 ± 12 | 69 ± 12 | 67 ± 12 | 68 ± 12 | 67 ± 12 |
| Age group | < 60 years | 8672 (23) | 6603 (26) | 1699 (17) | 1423 (22) | 1274 (20) | 1110 (22) | 714 (16) | 506 (20) | 520 (16) | 379 (18) | 642 (22) | 567 (26) | 223 (22) | 194 (24) |
| 60‐69 years | 8865 (23) | 6559 (26) | 2280 (23) | 1815 (27) | 1390 (22) | 1191 (23) | 1043 (23) | 720 (29) | 725 (22) | 530 (26) | 662 (23) | 553 (25) | 273 (27) | 222 (28) | |
| 70‐79 years | 10 528 (28) | 7286 (29) | 3144 (32) | 2230 (34) | 2122 (33) | 1733 (34) | 1394 (31) | 831 (33) | 968 (30) | 664 (32) | 1000 (35) | 770 (35) | 332 (32) | 261 (32) | |
| ≥80 years | 9764 (26) | 4622 (18) | 2622 (27) | 1137 (17) | 1682 (26) | 1062 (21) | 1335 (30) | 444 (18) | 1045 (32) | 484 (24) | 589 (20) | 282 (13) | 200 (19) | 130 (16) | |
| Tumor location 2 | Gastric cardia | 12 731 (48) | 7387 (42) | 2630 (37) | 1622 (33) | 2024 (55) | 1520 (54) | 1387 (39) | 737 (35) | 857 (39) | 480 (32) | 461 (27) | 314 (23) | 96 (12) | 70 (11) |
| Gastric fundus/body | 4461 (17) | 2992 (17) | 1576 (22) | 1132 (23) | 483 (13) | 368 (13) | 1018 (28) | 611 (29) | 486 (22) | 322 (22) | 459(27) | 414 (30) | 423 (52) | 342 (53) | |
| Gastric antrum/pylorus | 9578 (36) | 7208 (41) | 2957 (41) | 2236 (45) | 1152 (32) | 939 (33) | 1196 (33) | 762 (36) | 865 (39) | 678 (46) | 779 (46) | 654 (47) | 291 (36) | 237 (37) | |
| Other | 11 059 (29) | 7483 (30) | 2582 (27) | 1615 (24) | 2809 (43) | 2269 (45) | 885 (20) | 391 (16) | 1050 (32) | 577 (28) | 1194 (41) | 790 (36) | 218 (21) | 158 (20) | |
| Histology | Adenocarcinoma | 28 795 (76) | 19 231 (77) | 7316 (75) | 4869 (74) | 5100 (79) | 3979 (78) | NA | NA | 2785 (85) | 1771 (86) | 2693 (93) | 2069 (95) | 626 (61) | 503 (62) |
| Signet ring cell carcinoma | 6780 (18) | 4586 (18) | 1850 (19) | 1333 (20) | 972 (15) | 802 (16) | NA | NA | 278 (9) | 178 (9) | 74 (3) | 48 (2) | 283 (28) | 221 (27) | |
| Other 3 | 2254 (6) | 1253 (5) | 579 (6) | 403 (6) | 396 (6) | 315 (6) | NA | NA | 195 (6) | 108 (5) | 126 (4) | 55 (3) | 119 (12) | 83 (10) | |
| Differentiation 4 | Well | 1923 (6) | 1487 (6) | 261 (4) | 211 (4) | 60 (12) | 479 (11) | – | – | 101 (4) | 68 (4) | 223 (10) | 184 (10) | 66 (8) | 53 (8) |
| Moderate | 9737 (29) | 6753 (29) | 1738 (28) | 1369 (29) | 1729 (31) | 1371 (31) | – | – | 694 (28) | 491 (30) | 594 (27) | 501 (27) | 249 (29) | 203 (29) | |
| Poor/undifferentiated | 21 399 (65) | 14 968 (65) | 4310 (68) | 3163 (67) | 3158 (57) | 2590 (58) | – | – | 1659 (68) | 1099 (66) | 1396 (63) | 1139 (62) | 554 (64) | 447 (64) | |
| Local invasion 5 | Lamina propria/submucosa | 11 585 (34) | 7070 (29) | 1335 (17) | 1219 (19) | 1426 (23) | 1114 (22) | 545 (15) | 432 (18) | 250 (15) | 195 (15) | 483 (20) | 447 (21) | 182 (20) | 164 (21) |
| Muscularis propria/subserosa | 14 824 (43) | 11 791 (48) | 4278 (53) | 3509 (55) | 2887 (47) | 2451 (49) | 1950 (53) | 1199 (51) | 669 (39) | 540 (42) | 1061 (43) | 978 (46) | 515 (56) | 424 (55) | |
| Serosa | 5071 (15) | 4373 (18) | 1509 (19) | 1283 (20) | 1609 (26) | 1326 (26) | 804 (22) | 570 (24) | 582 (34) | 417 (33) | 722 (29) | 614 (29) | 184 (20) | 157 (20) | |
| Adjacent structures | 3032 (9) | 1569 (6) | 910 (11) | 368 (6) | 268 (4) | 157 (3) | 383 (10) | 144 (6) | 213 (12) | 125 (10) | 190 (8) | 93 (4) | 39 (4) | 24 (3) | |
| Positive lymph node 6 | 0 | 20 041 (54) | 11 631 (47) | 4030 (47) | 2955 (46) | 2787 (46) | 2228 (45) | 2274 (55) | 1275 (51) | 1793 (73) | 991 (66) | 1128 (44) | 855 (40) | 503 (54) | 401 (52) |
| 1‐6 | 12 359 (33) | 9040 (36) | 3414 (40) | 2418 (37) | 2381 (39) | 1908 (38) | 1385 (34) | 849 (34) | 545 (22) | 408 (27) | 808 (31) | 720 (33) | 332 (35) | 282 (36) | |
| ≥ 7 | 4507 (12) | 4335 (17) | 1138 (13) | 1081 (17) | 948 (16) | 856 (17) | 464 (11) | 361 (15) | 126 (5) | 94 (6) | 638 (25) | 578 (27) | 103 (11) | 95 (12) | |
| Harvested node no. | ∖ | 15 ± 13 | ∖ | 16 ± 16 | ∖ | NA | ∖ | 18 ± 14 | ∖ | NA | ∖ | NA | ∖ | NA | |
| Resection type 7 | Partial/subtotal gastrectomy | ∖ | 16 764 (67) | ∖ | 4564 (69) | ∖ | NA | ∖ | 860 (62) | ∖ | NA | ∖ | NA | ∖ | NA |
| Total/near‐total gastrectomy | ∖ | 5075 (20) | ∖ | 1656 (25) | ∖ | NA | ∖ | 475 (34) | ∖ | NA | ∖ | NA | ∖ | NA | |
| Other | ∖ | 3231 (13) | ∖ | 385 (6) | ∖ | NA | ∖ | 50 (4) | ∖ | NA | ∖ | NA | ∖ | NA | |
| Resection margin 8 | Positive | ∖ | NA | ∖ | 886 (15) | ∖ | NA | ∖ | 338 (15) | ∖ | NA | ∖ | 68 (7) | ∖ | NA |
| Neoadjuvant CHT 9 | Yes | ∖ | NA | ∖ | 2326 (35) | ∖ | 1155 (23) | ∖ | 840 (34) | ∖ | NA | ∖ | 124 (6) | ∖ | NA |
| Neoadjuvant RT 9 | Yes | ∖ | 2509 (10) | ∖ | 183 (3) | ∖ | 204 (4) | ∖ | 188 (8) | ∖ | NA | ∖ | 61 (3) | ∖ | NA |
| Total/adjuvant CHT 9 | Yes | 16 872 (45) | 11 694 (47) | 3176 (33) | 1251 (19) | 2543 (39) | 1646 (32) | NA | NA | 614 (19) | 453 (22) | 813 (28) | 620 (29) | 177 (17) | 134 (17) |
| Total/adjuvant RT 9 | Yes | 12 071 (32) | 5766 (23) | 810 (8) | 215 (3) | 1037 (16) | 645 (13) | NA | NA | 188 (6) | 88 (4) | 695 (24) | 563 (26) | 36 (4) | 34 (4) |
Categorical data are shown as count (percentage [%]), and numeric data as mean ± standard deviation. Records are complete otherwise specified below. Missing values are shown below.
The percentages of gastric cardia, fundus/body, and antrum/pylorus cancers are the proportions compared to the total tumor cases of the three locations; “other” includes lesser curvature, greater curvature, and overlapping lesion of stomach and stomach (NOS), and its proportion is relative to the whole cases.
Cystic/mucinous/serous (excluding signet ring cell), squamous cell, ductal/lobular, complex, unspecified, and epithelial (NOS) neoplasms.
Unknown differentiation: total patients: the United States, 4770 (13%); the Netherlands, 3436 (35%); Belgium, 941 (15%); Sweden, 3507 (78%); Norway, 804 (25%); Slovenia, 680 (24%); Estonia, 159 (15%); resected patients: the United States, 1862 (7%); the Netherlands, 1862 (28%); Belgium, 656 (13%); Sweden, 1552 (62%); Norway, 399 (19%); Slovenia, 348 (16%); Estonia, 104 (13%).
Unknown tumor local invasion: total patients: the United States, 3317 (9%); the Netherlands, 1713 (18%); Belgium, 278 (4%); Sweden, 804 (18%); Norway, 1544 (47%); Slovenia, 437 (15%); Estonia, 108 (11%); resected patients: the United States, 267 (1%); the Netherlands, 226 (3%); Belgium, 48 (1%); Sweden, 156 (6%); Norway, 780 (38%); Slovenia, 40 (2%); Estonia, 38 (5%). Invasion of serosa and adjacent structures could not be differentiated from each other in Norway or Slovenia.
Unknown positive lymph node: total patients: the United States, 922 (2%); the Netherlands, 1163 (12%); Belgium, 352 (5%); Sweden, 363 (8%); Norway, 794 (24%); Slovenia, 319 (11%); Estonia, 90 (9%); resected patients: the United States, 64 (<1%); the Netherlands, 151 (2%); Belgium, 104 (2%); Sweden, 16 (1%); Norway, 564 (27%); Slovenia, 19 (1%); Estonia, 95 (12%).
Gastrectomy (NOS) or local resection. Available in Sweden since 2010.
Unkown resection margin for resected nonmetastatic cancer: the Netherlands, 628 (10%); Sweden, 286 (11%); Slovenia, 26 (3%). In Slovenia, margin status was not available before 2009.
Nonsurgical therapies in the United States and Estonia had low sensitivity, and the counterpart category of “Yes” was “No/unknown.” In Norway and Estonia, neoadjuvant and adjuvant therapies could not be distinguished from each other. Total CHT/RT is for total patients, and (neo)adjuvant CHT/RT for resected patients.
CHT, chemotherapy; RT, radiotherapy; NOS, not otherwise specified; ∖, resection‐specific variables not applicable for total patients; ‐, not shown due to >60% missing values; NA, not available.